|
|
Volumn 30, Issue 3, 2013, Pages
|
|
Phase II study of weekly PM00104 (ZALYPSIS®) in patients with pretreated advanced/metastatic endometrial or cervical cancer
a
d
PHARMAMAR S A
(Spain)
|
|
Author keywords
Cervical cancer; Endometrial cancer; Phase II; PM00104; Second line; Single agent
|
|
Indexed keywords
ANTHRACYCLINE DERIVATIVE;
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC ALKALOID;
FOLIC ACID DERIVATIVE;
IMMUNOMODULATING AGENT;
MONOCLONAL ANTIBODY;
PLATINUM DERIVATIVE;
PM 100104;
PYRIMIDINE DERIVATIVE;
TAXANE DERIVATIVE;
UNCLASSIFIED DRUG;
ZALYPSIS;
PM 00104;
TETRAHYDROISOQUINOLINE DERIVATIVE;
ADULT;
ADVANCED CANCER;
AGED;
ANEMIA;
ANOREXIA;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
ASTHENIA;
CANCER CHEMOTHERAPY;
CANCER RADIOTHERAPY;
CLINICAL ARTICLE;
CONSTIPATION;
DIARRHEA;
DRUG INFUSION;
DRUG SAFETY;
DRUG WITHDRAWAL;
ENDOMETRIUM CANCER;
FEMALE;
FEVER;
FOLLOW UP;
HUMAN;
LEUKOPENIA;
LYMPHOCYTOPENIA;
METASTASIS;
MIDDLE AGED;
MONOTHERAPY;
MULTIPLE CYCLE TREATMENT;
NAUSEA;
NEUTROPENIA;
NIGHT SWEAT;
OPEN STUDY;
OVERALL SURVIVAL;
PATIENT COMPLIANCE;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
THROMBOCYTOPENIA;
TREATMENT OUTCOME;
UTERINE CERVIX CANCER;
VOMITING;
CLINICAL TRIAL;
DISEASE FREE SURVIVAL;
ENDOMETRIAL NEOPLASMS;
UTERINE CERVICAL NEOPLASMS;
ENDOMETRIUM TUMOR;
UTERINE CERVIX TUMOR;
ADULT;
AGED;
ANTINEOPLASTIC AGENTS;
DISEASE-FREE SURVIVAL;
ENDOMETRIAL NEOPLASMS;
FEMALE;
HUMANS;
MIDDLE AGED;
TETRAHYDROISOQUINOLINES;
UTERINE CERVICAL NEOPLASMS;
|
|
EID: 84878818183
PISSN: 13570560
EISSN: 1559131X
Source Type: Journal
DOI: 10.1007/s12032-013-0627-3 Document Type: Article |
|
Times cited : (15)
|
|
References (10)
|
